Background-It has been suggested that black race predicts stent thrombosis (ST) after drug-eluting stent implantation. Whether socioeconomic status or comorbid conditions confound the contribution of black race to the development of ST is unclear.
T he advent of drug-eluting stents (DES) has changed the landscape of in-stent restenosis treatment and has been associated with a remarkable reduction in the need for repeat target vessel revascularization. This has led to widespread application of this technology, currently used in 75% of patients undergoing percutaneous coronary intervention (PCI) in the United States. DES, however, have not been associated with decreased rates of death or myocardial infarction (MI) 1 and have been associated with the alarming, yet rare, phenomenon of late stent thrombosis (ST). This has led to a mandatory requirement of prolonged dual antiplatelet therapy administration (Ն12 months) to prevent the occurrence of ST. 2 Although dual antiplatelet therapy reduces the risk of ST, it has not eliminated this phenomenon, which continues to occur in patients receiving dual antiplatelet therapy and is associated with high rates of morbidity and mortality. 3, 4 
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Although the greatest risk of ST occurs in the first 30 days, 5 late ST and very late ST remain a concern because of their unpredictable nature of occurrence and course. Premature cessation of dual antiplatelet therapy has consistently been a leading predictor of ST; other predictors are related to complex lesion and patient confounders. 3, 4, 6 Numerous large-scale studies have demonstrated that blacks have more modifiable risk factors for coronary artery disease and higher cardiovascular mortality than their white counterparts. [7] [8] [9] Despite historically similar presentation and natural history of MI, black race has been reported to be an independent predictor of mortality after PCI and coronary bypass graft surgery. 10, 11 Outcomes after PCI have been controversial, however, because some studies have reported more in-hospital deaths/ST-segment elevation MIs and increased risk of death over time and others have demonstrated no difference in outcomes. [12] [13] [14] We reported previously that although blacks experience higher rates of major cardiac events after PCI, socioeconomic disparities may have an impact on clinical outcome in patients undergoing DES implantation. 15 Here, we aimed to examine the incidence of early, late, and very late ST in the black population in a high-volume PCI center and to determine whether socioeconomic status or comorbid conditions confound the contribution of black race to the development of ST.
Methods

Study Group and Design
A retrospective analysis of 7236 consecutive patients who underwent PCI of 13 135 lesions from April 2003 to December 2008 and received Ն1 DES was conducted. Black patients were compared with nonblack patients. Clinical outcomes during the initial hospitalization, at 30 days, and at 12, 24, and 36 months were assessed. This study was conducted under the approval of the local Institutional Review Board. Systematic chart review of patients undergoing coronary angioplasty was performed to acquire baseline demographics, risk factors, procedural characteristics, and overall hospital course. Information was obtained at the time of the procedure, and follow-up was acquired by mail, telephone contact, or office visit. Medical record review to confirm adverse events was performed by an independent clinical event committee.
The interventional strategy, including the type of stent implanted and anticoagulation regimen, was conducted at the operator's discretion. PCI was performed according to guidelines at the time of the procedure. 16 Intraprocedural anticoagulation was ensured through the use of unfractionated heparin or bivalirudin, with or without a glycoprotein IIb/IIIa inhibitor, to achieve an activated clotting time of Ͼ250 seconds in all patients. Patients received a 325-mg loading dose of aspirin and were encouraged to continue this regimen indefinitely. Clopidogrel was administered as a loading dose of 300 to 600 mg at the time of DES implantation and maintained at a dose of 75 mg/d. Clopidogrel therapy was recommended for a minimum of 3 to 12 months after Cypher sirolimus-eluting stent (Cordis, Johnson & Johnson, Miami Lakes, Fla) implantation and a minimum of 6 to 12 months after Taxus paclitaxel-eluting stent (Boston Scientific, Natick, Mass) implantation. Patients receiving DES in the setting of acute coronary syndrome or MI were encouraged to continue clopidogrel therapy for Ն12 months.
Outcomes analyzed included ST, all-cause death, Q-wave MI, and target vessel revascularization. ST was classified according to the Academic Research Consortium definitions of event timing and certainty. Only definite STs were included, defined as pathological or angiographic confirmation of thrombus within a stent in a patient presenting with acute coronary syndrome. Timing of ST was classified as early, late, or very late (Ͻ30 days, 30 days to 1 year, and Ͼ1 year after PCI, respectively). Angiographic success was defined as Ͼ20% reduction in the percent diameter stenosis of the lesion and a final residual stenosis of Ͻ50%. Q-wave MI was defined as the appearance of new pathological Q waves in the coronary distribution of the treated artery with an increase in creatine kinase-MB to Ն2 times the reference values. Target vessel revascularization was defined as revascularization occurring in any area along the previously treated vessel.
Clopidogrel compliance was expressed as a time-dependent covariate defined as the days to cessation for those patients who ceased their prescription. Race was patient defined and recorded on admission. Patients identified themselves as black, Asian, white, Hispanic, or Native American and were allowed to select only 1 race. ZIP codes were abstracted from the hospital billing database and matched with census bureau data on median household income by ZIP code. 17
Statistical Analysis
Continuous variables are presented as meanϮSD, and categorical variables are presented as percentages. Household income is presented as median income for the patient's ZIP code and the interquartile range. Differences in continuous variables between groups were compared by use of the t test or Wilcoxon rank-sum test as appropriate. Proportions were compared by use of the 2 test or Fisher exact test when appropriate. A value of PϽ0.05 was considered statistically significant. To test the independent effect of black race on time to event, a Cox proportional-hazards model was constructed. Several studies have identified clopidogrel cessation, median household income, age, history of diabetes mellitus, history of chronic renal insufficiency, history of congestive heart failure, history of in-stent restenosis, and presentation with MI as independent predictors of ST and suggested an inverse relationship between age and the risk of ST. Therefore, these covariates were selected for the model as potential confounders. 18 -20 The proportional-hazards assumption for such covariates was then tested. Covariates remaining in the model were expressed as hazard ratios with 95% confidence intervals. Statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary, NC).
Results
Population
The study included 7236 patients who underwent PCI from April 2003 to December 2008. Of those, 22% were black and 78% were nonblack. A total of 65.7% were men, and the average age at presentation was 65Ϯ13 years. The median household income (per $10 000) was significantly lower in the black group ($44 197 [25th to 75th percentile, $35 313 to $61 374] versus $60 838 [25th to 75th percentile, $50 844 to $74 933]; PϽ0.001). Blacks were younger and were more likely to have a history of hypertension, diabetes mellitus, chronic renal insufficiency, and congestive heart failure ( Table 1) .
Blacks had fewer diseased vessels (1.85Ϯ0.86 versus 1.96Ϯ0.87; Pϭ0.005) and less history of in-stent restenosis (4.4% versus 5.4%; Pϭ0.035). Angiographic success (lesion based) was high in both groups (black, 97.9% versus nonblack, 98.2%). Of the patients who presented with ST, 82 received sirolimus stents, 26 received paclitaxel stents, 1 received a zotarolimus stent, and 2 received a combination of sirolimus and paclitaxel stents ( Table 1 ).
Outcomes
The rate of early ST at 30 days was 0.83Ϯ0.21% and late ST at 1 year was 1.11Ϯ0.25%. The rates of very late ST were 1.46Ϯ0.29% and 1.76Ϯ0.35% at 2 and 3 years, respectively, as shown by Kaplan-Meier analysis ( Table 2 ). The cumulative incidence of late ST from 30 days to 1 year was 0.24%/y, which increased to 0.36%/y from 1 to 2 years. In a comparison of the black population and the nonblack populations, the incidence of early ST at 30 days was 1.71% versus 0.59%; late ST at 1 year, 2.25% versus 0.79%; late ST at 2 years, 2.78% versus 1.09%; and late ST at 3 years, 3.67% versus 1.25% (the Figure) . Black race was associated with serious morbidity and mortality; short-and long-term outcomes revealed significantly higher rates of all-cause death and death/MI at 30 days and 12, 24, and 36 months. At 36 months, the rate of all-cause death in blacks was 24.9% compared with 13.1% in nonblacks (PϽ0.001), and the rate of death/MI in blacks was 29.8% versus 15.9% in nonblacks (PϽ0.0001). At the time of ST, blacks were numerically more likely to be taking clopidogrel, although the difference was not statistically significant (87.5% of blacks versus 77.8% of nonblacks; Pϭ0.068). Of the patients who stopped clopidogrel before the ST event, the median time to cessation was 11 days (25th to 75th percentile, 3.5 to 384 days) and 18 days (25th to 75th percentile, 4 to 397 days; Pϭ0.699) in the black and nonblack populations, respectively.
On multivariate analysis, clopidogrel cessation, black race, history of diabetes mellitus, history of congestive heart failure, and previous PCI were independent predictors of early ST (Ͻ30 days). On further examination, black race emerged as the strongest independent predictor of late ST (Ͼ30 days), whereas history of diabetes mellitus was no longer predictive after 30 days (Table 3 ).
Discussion
The main findings of this large, unrestricted, single-center registry in the United States for all patients who underwent PCI with DES implantation were a 0.85% incidence of early ST at 30 days and rates of late and very late ST of 0.24%/y to 0.36%/y at the 3-year follow-up. These rates were especially higher in the black population, who had a Ͼ2-fold increased risk incidence of ST, despite a high rate of compliance with dual antiplatelet therapy. In a multivariate model of ST at 30 days, black race was a strong independent predictor of early ST. In a similar multivariate analysis of ST beyond 30 days, black race persisted as an independent predictor of late ST.
Black race is an independent predictor of ST even when accounting for potential confounders such as socioeconomic status and comorbidities. Socioeconomic status has been associated with worse outcome after coronary revascularization and a greater burden of cardiovascular disease. 11, [21] [22] [23] Our evaluation used median income to represent socioeco- nomic status. Consistent with previous studies in a similar patient population, the median income of black patients was lower than that of nonblacks in our study. 15 Although the median income of each group differed, income was not a predictor of ST and therefore cannot account for the increased risk of ST in the black population.
Although differences in socioeconomic status may not explain the increased rate of ST in the black population in this study, discrepancies in access to care have been a concern in studies of racial disparities in health care. Several studies have demonstrated that blacks undergo fewer coronary revascularization procedures than whites, 24, 25 even patients with equal access to Medicare benefits. 26, 27 Black Medicare beneficiaries have been shown to have higher mortality even after adjustment for confounding variables. 28 Because our entire study population underwent PCI, a discrepancy in access to revascularization procedures is less of an issue. "Access to care" in a broader sense is worth mentioning, however, because it relates to follow-up and medication compliance. Despite a lower median income, more blacks in our study were compliant with clopidogrel therapy at the time of ST, although the difference was not significant (blacks, 87.5% versus nonblacks, 77.8%; Pϭ0.068). In addition, previous studies have demonstrated that being financial incapable of complying with clopidogrel therapy is an infrequent reason for clopidogrel cessation. 29 This highlights the fact that socioeconomic disparities in our study population did not seem to affect clopidogrel compliance or the incidence of ST.
Because the traditional socioeconomic factors that plague racial disparities in health care have been accounted for in our study, further mechanisms such as genetic differences by which black race predicts ST must be pursued. Previous studies have demonstrated that carriers of a reduced-function CYP2C19 allele have significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and an increased rate of cardiovascular events, including ST. 30, 31 This polymorphism has been observed in a higher rate of blacks and East Asians compared with whites. 32 A genetic influence on the mechanism of ST in blacks is a possibility and deserves further investigation.
Limitations
This study was a retrospective analysis and is therefore prone to the shortcomings of any prospective study. Any confounding variables not represented in the model could potentially affect outcomes. Another limitation of our study is use of the Academic Research Consortium definitions of definite ST, which require angiographic or pathological confirmation; we did not include probable or possible ST. These factors may result in an underestimation of the true incidence of ST. Furthermore, race was self-reported, which is the preferred method in federal guidelines. Our study, however, reported race in mutually exclusive categories. This does not account for patients who may identify with more than 1 race or ethnicity.
We observed a significant difference in socioeconomic status in the black and nonblack populations. This evaluation used median income by ZIP code to assess socioeconomic status. The use of ZIP code as an aggregate measure of socioeconomic status is controversial because of the large number of residents covered and potential heterogeneity of the population. This heterogeneity may be the explanation for the small to moderate correlation for median income between ZIP code and microlevel data demonstrated in several studies. 33, 34 ZIP codes, however, may in fact be a more accurate representation of some populations because smaller aggregate proxies tend to exclude rural residents. In addition, this study did not include data on substance abuse; however, because several studies have reported an association between cocaine use and ST, this issue may warrant further investigation in the future.
In reference to medication compliance, although careful attention was paid to questioning patients on length of treatment, any self-reported medical compliance data are subject to recall bias. The transient cessation of clopidogrel throughout the follow-up duration in this population may be underrepresented; however, all attempts were made to assess the compliance of clopidogrel at the time of ST. This may not account for smaller differences in income in our region with a high population density.
Conclusions
This is the first study to demonstrate black race as an independent predictor of ST after DES implantation. Because our analysis adjusts for traditional variables associated with racial disparities in health care, further mechanisms such as genetic polymorphisms and responsiveness to antiplatelet therapy must be pursued.
